Clinical Trials Finder
Independent ClinicalTrials.gov directory
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced May 22, 2026, 12:01 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 25–48 of 24 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Metastatic Invasive Breast Cancer Clear all
Active, not recruiting Not applicable Interventional
View directory record Official record
Conditions
Anatomic Stage 0 Breast Cancer AJCC v8, Anatomic Stage I Breast Cancer AJCC v8, Anatomic Stage IA Breast Cancer AJCC v8, Anatomic Stage IB Breast Cancer AJCC v8, Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIA Breast Cancer AJCC v8, Anatomic Stage IIB Breast Cancer AJCC v8, Invasive Breast Carcinoma, Non-Metastatic Breast Carcinoma, Prognostic Stage 0 Breast Cancer AJCC v8, Prognostic Stage I Breast Cancer AJCC v8, Prognostic Stage IA Breast Cancer AJCC v8, Prognostic Stage IB Breast Cancer AJCC v8, Prognostic Stage II Breast Cancer AJCC v8, Prognostic Stage IIA Breast Cancer AJCC v8, Prognostic Stage IIB Breast Cancer AJCC v8, Prognostic Stage III Breast Cancer AJCC v8, Prognostic Stage IIIA Breast Cancer AJCC v8, Prognostic Stage IIIB Breast Cancer AJCC v8, Prognostic Stage IIIC Breast Cancer AJCC v8
Interventions
Quality-of-Life Assessment, Questionnaire Administration, Radiation Boost, Therapeutic Surgical Procedure, Whole Breast Irradiation, Breast MRI
Other · Radiation · Procedure
Lead sponsor
Rutgers, The State University of New Jersey
Other
Eligibility
18 Years and older
Enrollment
103 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2028
U.S. locations
11
States / cities
Belleville, New Jersey • Elizabeth, New Jersey • Hamilton, New Jersey + 7 more
Source: ClinicalTrials.gov public record
Updated Jan 21, 2026 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Acute Myeloid Leukemia, Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Clinical Stage IV Esophageal Adenocarcinoma AJCC v8, Clinical Stage IV Gastric Cancer AJCC v8, Clinical Stage IV Gastroesophageal Junction Adenocarcinoma AJCC v8, Esophageal Carcinoma, Fallopian Tube Carcinoma, Gastric Carcinoma, Hormone Receptor-Positive Breast Carcinoma, Invasive Breast Carcinoma, Lung Non-Small Cell Carcinoma, Lung Small Cell Carcinoma, Malignant Solid Neoplasm, Melanoma, Metastatic Prostate Carcinoma, Multiple Myeloma, Ovarian Carcinoma, Ovarian High Grade Serous Adenocarcinoma, Primary Peritoneal Carcinoma, Stage III Fallopian Tube Cancer AJCC v8, Stage III Lung Cancer AJCC v8, Stage III Ovarian Cancer AJCC v8, Stage IV Colorectal Cancer AJCC v8, Stage IV Fallopian Tube Cancer AJCC v8, Stage IV Lung Cancer AJCC v8, Stage IV Ovarian Cancer AJCC v8, Stage IVB Prostate Cancer AJCC v8, Triple-Negative Breast Carcinoma
Interventions
Biospecimen Collection, Computed Tomography, Magnetic Resonance Imaging, Medical Chart Review, Paracentesis, Positron Emission Tomography
Procedure · Other
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
13 Years and older
Enrollment
1,600 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
147
States / cities
Daphne, Alabama • Fairhope, Alabama • Mobile, Alabama + 115 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Estrogen-receptor Positive Invasive Metastatic Breast Cancer
Interventions
Ruxolitinib, Exemestane
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older · Female only
Enrollment
25 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2016
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 11, 2024 · Synced May 22, 2026, 12:01 AM EDT
Suspended Phase 2 Interventional
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Cancer
Interventions
Taletrectinib
Drug
Lead sponsor
Megan Kruse, MD
Other
Eligibility
18 Years and older
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2030
U.S. locations
2
States / cities
Weston, Florida • Cleveland, Ohio
Source: ClinicalTrials.gov public record
Updated Apr 30, 2025 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 3 Interventional
View directory record Official record
Conditions
Depression, Breast Cancer, Stress, Breast Cancer Non-invasive Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Cancer Metastatic Breast Cancer
Interventions
Videoconferencing support group
Behavioral
Lead sponsor
Stanford University
Other
Eligibility
21 Years and older · Female only
Enrollment
100 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008 – 2010
U.S. locations
1
States / cities
Stanford, California
Source: ClinicalTrials.gov public record
Updated Dec 5, 2010 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer Stage IV, Unresectable Locally Advanced Invasive Breast Cancer, Metastatic Invasive Breast Cancer
Interventions
Palbociclib, Bazedoxifene
Drug
Lead sponsor
Dana-Farber Cancer Institute
Other
Eligibility
18 Years and older · Female only
Enrollment
36 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2021
U.S. locations
2
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Oct 23, 2022 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, Metastatic Breast Carcinoma, Invasive Breast Carcinoma
Interventions
Carboplatin, Cyclophosphamide, Thiotepa, Stem Cell Transplant
Drug · Procedure
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years to 55 Years
Enrollment
32 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Apr 9, 2013 · Synced May 22, 2026, 12:01 AM EDT
Terminated Early Phase 1 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Astrocytoma, Breast Carcinoma Metastatic in the Brain, Glioma, Invasive Breast Carcinoma, Oligodendroglioma, Prognostic Stage IV Breast Cancer AJCC v8, Recurrent Glioma
Interventions
Best Practice, Ketoconazole
Other · Drug
Lead sponsor
Wake Forest University Health Sciences
Other
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2022
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Source: ClinicalTrials.gov public record
Updated Mar 19, 2026 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 1 Interventional
View directory record Official record
Conditions
Estrogen Receptor Positive, HER2/Neu Negative, Invasive Breast Carcinoma, Multifocal Breast Carcinoma, Postmenopausal, Progesterone Receptor Positive, Stage I Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIA Breast Cancer, Stage IIB Breast Cancer, Stage III Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer, Stage IV Breast Cancer
Interventions
Biopsy of Breast, Copanlisib, Laboratory Biomarker Analysis, Letrozole, Palbociclib, Pharmacological Study
Procedure · Drug · Other
Lead sponsor
Jonsson Comprehensive Cancer Center
Other
Eligibility
19 Years and older
Enrollment
10 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Los Angeles, California
Source: ClinicalTrials.gov public record
Updated Sep 25, 2022 · Synced May 22, 2026, 12:01 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Cancer
Interventions
counseling intervention, educational intervention, psychosocial assessment and care, quality-of-life assessment
Other · Procedure
Lead sponsor
Dartmouth-Hitchcock Medical Center
Other
Eligibility
18 Years and older
Enrollment
329 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2013
U.S. locations
2
States / cities
Lebanon, New Hampshire • White River Junction, Vermont
Source: ClinicalTrials.gov public record
Updated Dec 18, 2014 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Breast Cancer
Interventions
PD0332991, Paclitaxel
Drug
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2019
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 7, 2020 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional
View directory record Official record
Conditions
Hormone Receptor-positive Human Epidermal Growth Factor 2-negative, Metastatic Invasive LObular Carcinoma
Interventions
Fulvestrant, Repotrectinib
Drug
Lead sponsor
M.D. Anderson Cancer Center
Other
Eligibility
18 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2024 – 2025
U.S. locations
1
States / cities
Houston, Texas
Source: ClinicalTrials.gov public record
Updated Jan 4, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 2 Interventional Results available
View directory record Official record
Conditions
HER2-Positive Breast Carcinoma, Invasive Breast Carcinoma, Metastatic Malignant Neoplasm in the Brain, Recurrent Breast Carcinoma, Stage IV Breast Cancer AJCC v6 and v7
Interventions
Laboratory Biomarker Analysis, Lapatinib Ditosylate, Stereotactic Radiosurgery, Whole-Brain Radiotherapy
Other · Drug · Radiation
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
143 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2022
U.S. locations
292
States / cities
Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 210 more
Source: ClinicalTrials.gov public record
Updated Oct 16, 2023 · Synced May 22, 2026, 12:01 AM EDT
Terminated No phase listed Observational
View directory record Official record
Conditions
Adenocarcinoma of the Breast
Interventions
Not listed
Lead sponsor
Indiana University
Other
Eligibility
18 Years to 80 Years · Female only
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2010 – 2022
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Mar 27, 2012 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting No phase listed Observational
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Breast Carcinoma, Peritoneal Effusion, Recurrent Breast Carcinoma
Interventions
Biospecimen Collection, Medical Chart Review
Procedure · Other
Lead sponsor
Mayo Clinic
Other
Eligibility
18 Years and older
Enrollment
300 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2029
U.S. locations
14
States / cities
Birmingham, Alabama • San Francisco, California • Washington D.C., District of Columbia + 11 more
Source: ClinicalTrials.gov public record
Updated May 14, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 1 Interventional
View directory record Official record
Conditions
Metastatic Lobular Breast Carcinoma
Interventions
[68Ga]Ga DOTA-5G
Drug
Lead sponsor
University of California, Davis
Other
Eligibility
18 Years to 89 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2025 – 2027
U.S. locations
1
States / cities
Sacramento, California
Source: ClinicalTrials.gov public record
Updated Mar 22, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Not applicable Interventional
View directory record Official record
Conditions
Breast Cancer, Long-term Effects Secondary to Cancer Therapy in Adults, Skin Reactions Secondary to Radiation Therapy
Interventions
adjuvant therapy, conventional surgery, 3-dimensional conformal radiation therapy, brachytherapy, intracavitary balloon brachytherapy, proton beam radiation therapy
Procedure · Radiation
Lead sponsor
Abramson Cancer Center at Penn Medicine
Other
Eligibility
18 Years to 120 Years · Female only
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2005 – 2009
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Apr 8, 2020 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Anatomic Stage III Breast Cancer AJCC v8, Anatomic Stage IV Breast Cancer AJCC v8, Breast Adenocarcinoma, Invasive Breast Carcinoma, Malignant Solid Neoplasm
Interventions
Biopsy Procedure, Blood Sample, Bone Scan, Computed Tomography, Entinostat, Ipilimumab, Nivolumab, Pharmacogenomic Study, Pharmacological Study, Positron Emission Tomography
Procedure · Other · Drug + 1 more
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
57 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2026
U.S. locations
5
States / cities
Duarte, California • New Haven, Connecticut • Baltimore, Maryland + 1 more
Source: ClinicalTrials.gov public record
Updated Apr 12, 2026 · Synced May 22, 2026, 12:01 AM EDT
Terminated Phase 2 Interventional Results available
View directory record Official record
Conditions
Breast Cancer, CNS Disease
Interventions
ZK219477
Drug
Lead sponsor
Nancy Lin, MD
Other
Eligibility
18 Years and older · Female only
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2012
U.S. locations
1
States / cities
Boston, Massachusetts
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting Phase 2 Interventional Results available
View directory record Official record
Conditions
Invasive Breast Cancer, Metastatic Breast Cancer, HR-Positive Breast Cancer, HER2-negative Breast Cancer
Interventions
Pembrolizumab, Sacituzumab Govitecan
Drug
Lead sponsor
Ana C Garrido-Castro, MD
Other
Eligibility
18 Years and older
Enrollment
110 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2027
U.S. locations
8
States / cities
Atlanta, Georgia • Chicago, Illinois • Boston, Massachusetts + 5 more
Source: ClinicalTrials.gov public record
Updated Jan 14, 2026 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Not applicable Interventional
View directory record Official record
Conditions
Metastatic Invasive Breast Cancer
Interventions
Acceptance- and mindfulness-based physical activity promotion
Behavioral
Lead sponsor
University of Oklahoma
Other
Eligibility
18 Years to 99 Years
Enrollment
38 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026
U.S. locations
1
States / cities
Oklahoma City, Oklahoma
Source: ClinicalTrials.gov public record
Updated Mar 18, 2026 · Synced May 22, 2026, 12:01 AM EDT
Completed Phase 1 Interventional
View directory record Official record
Conditions
Adenocarcinoma of the Colon, Adenocarcinoma of the Gallbladder, Adenocarcinoma of the Pancreas, Adenocarcinoma of the Rectum, Adult Primary Hepatocellular Carcinoma, Advanced Adult Primary Liver Cancer, Cholangiocarcinoma of the Gallbladder, Diffuse Adenocarcinoma of the Stomach, Intestinal Adenocarcinoma of the Stomach, Male Breast Cancer, Mixed Adenocarcinoma of the Stomach, Ovarian Endometrioid Adenocarcinoma, Paget Disease of the Breast With Intraductal Carcinoma, Paget Disease of the Breast With Invasive Ductal Carcinoma, Recurrent Adult Primary Liver Cancer, Recurrent Breast Cancer, Recurrent Colon Cancer, Recurrent Gallbladder Cancer, Recurrent Gastric Cancer, Recurrent Malignant Testicular Germ Cell Tumor, Recurrent Pancreatic Cancer, Recurrent Rectal Cancer, Recurrent Salivary Gland Cancer, Salivary Gland Adenocarcinoma, Stage II Malignant Testicular Germ Cell Tumor, Stage II Pancreatic Cancer, Stage III Colon Cancer, Stage III Gastric Cancer, Stage III Malignant Testicular Germ Cell Tumor, Stage III Pancreatic Cancer, Stage III Rectal Cancer, Stage III Salivary Gland Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IV Breast Cancer, Stage IV Colon Cancer, Stage IV Gastric Cancer, Stage IV Pancreatic Cancer, Stage IV Rectal Cancer, Stage IV Salivary Gland Cancer, Thyroid Gland Medullary Carcinoma, Unresectable Gallbladder Cancer
Interventions
recombinant fowlpox-CEA(6D)/TRICOM vaccine, sargramostim, recombinant fowlpox GM-CSF vaccine adjuvant
Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
48 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2001
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jan 24, 2013 · Synced May 22, 2026, 12:01 AM EDT
Active, not recruiting Phase 1 Interventional
View directory record Official record
Conditions
Estrogen Receptor-positive Breast Cancer, HER2-negative Breast Cancer, Invasive Ductal Breast Carcinoma, Progesterone Receptor-positive Breast Cancer, Recurrent Breast Cancer, Stage IV Breast Cancer
Interventions
PI3K inhibitor BYL719, letrozole, laboratory biomarker analysis, pharmacological studies
Drug · Other
Lead sponsor
Vanderbilt-Ingram Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
46 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2025
U.S. locations
2
States / cities
Boston, Massachusetts • Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Jul 22, 2024 · Synced May 22, 2026, 12:01 AM EDT
Recruiting Phase 2 Interventional
View directory record Official record
Conditions
Anatomic Stage IV Breast Cancer AJCC v8, Invasive Breast Carcinoma, Metastatic Triple-Negative Breast Carcinoma
Interventions
Biopsy Procedure, Biospecimen Collection, Carboplatin, Computed Tomography, Durvalumab, Gemcitabine Hydrochloride, Magnetic Resonance Imaging, Nab-paclitaxel, Personalized Synthetic Long Peptide Vaccine, Poly ICLC, Sacituzumab Govitecan, Tremelimumab
Procedure · Drug · Biological
Lead sponsor
National Cancer Institute (NCI)
NIH
Eligibility
18 Years and older
Enrollment
70 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
30
States / cities
Orange, California • Sacramento, California • Aurora, Colorado + 22 more
Source: ClinicalTrials.gov public record
Updated May 12, 2026 · Synced May 22, 2026, 12:01 AM EDT